9 October 2024 US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company.
Boston-based Albireo Pharma, a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, closed more than 14% higher after Tuesday’s trading. 12 October 2022
Japanese pharma major Astellas today released positive 52-week results from the Phase III SKYLIGHT 4 clinical study evaluating the safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. 12 October 2022
Inflation across Europe has now risen above 10%. As a result, this has increased the manufacturing costs of essential, off patent medicines, which account for 70% of those dispensed in Europe. 12 October 2022
The global general anesthesia drugs market is anticipated to reach a valuation of $6.7 billion by 2032, with sales growing at a stagnant CAGR of 3.4% from 2022 to 2032, according to Future Market Insights. 12 October 2022
Swiss pharma giant Roche today announced new two-year data showing that its Evrysdi (risdiplam) improved or maintained motor function in people with spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatal. 12 October 2022
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy). 11 October 2022
Results from early stage research into AstraZeneca’s coronavirus vaccine has poured cold water onto hopes that a nasally-administered form of the jab could be developed soon. 11 October 2022
Reports hinting that Michelle McMurry-Heath’s days as president and chief executive of the Biotechnology Innovation Organization (BIO) might be numbered have circulated in recent days. 11 October 2022
Shares of Ginkgo Bioworks were down 3.6% at $2.78 today, despite the company announcing a deal with US pharma giant Merck & Co to engineer a crucial component of up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. 11 October 2022
Oxford, UK-based start-up Ochre Bio, an innovator in chronic liver disease drug development, yesterday announced the successful close of $30 million in Series A financing. 11 October 2022
Neumora Therapeutics, a US clinical-stage biotech focussed on brain diseases through the integration of data science and neuroscience that came out of stealth in July last year with $500 million financing, has added to its cash pile announcing today the close of a $112 million Series B financing. 11 October 2022
The UK’s BioIndustry Association (BIA), the trade body for innovative life sciences, has welcomed a one-year extension to the European Commission Decision Reliance Procedure (ECDRP). 11 October 2022
German pharma major Bayer had a boost for its Kerendia (finerenone), a non-steroidal mineralocorticoid receptor antagonist, with an important endorsement for the drug’s use. 11 October 2022
Positive Phase III trial results evaluating the investigational use of Dupixent (dupilumab) in children aged one to 11 years with active eosinophilic esophagitis (EoE) were presented today at United European Gastroenterology (UEG) Week 2022. 11 October 2022
Singapore-based TauRx Pharmaceuticals, a company that claims to be the global leader in tau-based research in Alzheimer’s disease, recently reported positive progress for the firm's lead investigative oral drug hydromethylthionine mesylate (HMTM). The drug was found to be effective in improving cognition in patients with early Alzheimer’s disease (AD). 11 October 2022
The European Commission has informed Israel-based generics behemoth Teva Pharmaceutical Industries of its preliminary view that the company has breached EU antitrust rules by engaging in practices intended to delay competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate). 10 October 2022
CMS released a Request for Information (RFI) and a sample list of prescription drugs that the agency preliminarily intends to include under the proposed Medicare $2 Drug List Model. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024